About: Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.17 (+0.16%)
KYTX NASDAQ Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc. Common Stock share price
KYTX price activity
Último preço
$ 6,170
Variação (24h)
0,01 USD (0,16%)
Volume
650.25K
Volume (média 4 sem.)
-
Abertura
$ 6,12
Variação do dia
$ 6,05 - $ 6,31
Fechamento anterior
$ 6,16
Último negócio
07 Oct, 8:00 pm GMT+0
Atrasado
07 Oct, 8:00 pm GMT+0
KYTX price performance
Atrasado
07 Oct, 8:00 pm GMT+0
quote.marketSignals